Biomaterial Integration in the Joint: Pathological Considerations, Immunomodulation, and the Extracellular Matrix

Abstract

Defects of articular joints are becoming an increasing societal burden due to a persistent increase in obesity and aging. For some patients suffering from cartilage erosion, joint replacement is the final option to regain proper motion and limit pain. Extensive research has been undertaken to identify novel strategies enabling earlier intervention to promote regeneration and cartilage healing. With the introduction of decellularized extracellular matrix (dECM), researchers have tapped into the potential for increased tissue regeneration by designing biomaterials with inherent biochemical and immunomodulatory signals. Compared to conventional and synthetic materials, dECM‐based materials invoke a reduced foreign body response. It is therefore highly beneficial to understand the interplay of how these native tissue‐based materials initiate a favorable remodeling process by the immune system. Yet, such an understanding also demands increasing considerations of the pathological environment and remodeling processes, especially for materials designed for early disease intervention. This knowledge will avoid rejection and help predict complications in conditions with inflammatory components such as arthritides. This review outlines general issues facing biomaterial integration and emphasizes the importance of tissue‐derived macromolecular components in regulating essential homeostatic, immunological, and pathological processes to increase biomaterial integration for patients suffering from joint degenerative diseases.

Cartilaginous Organoids: Advances, Applications, and Perspectives

“…Defects of articular joints are becoming an increasing societal burden. [ 6 ] It is growingly required to promote greater access to the mechanisms of cartilage diseases and therapeutic approaches. Current research on cartilage disease model is mainly through cell culture and animal experiments, but these 2D platform‐based studies cannot fully replace real human tissues and systems, [ 7 ] and better in vitro biological models are needed to provide tools for disease modeling and drug testing.…”